Table 2.

Concentrations of regorafenib in the heart, liver, spleen, lung, kidney and brain of rats after administration (16 mg/kg, p.o.) with or without radiotherapy.

Organ (µg/g)	Heart	Liver	Spleen	Lung	Kidneys	Brain
Regorafenib 16 mg/kg × 1 d	0.45 ± 0.31	1.46 ± 0.34	0.26 ± 0.10	0.47 ± 0.18	0.34 ± 0.19	0.03 ± 0.04
Regorafenib 16 mg/kg × 3 d	0.25 ± 0.10	1.45 ± 0.74	0.38 ± 0.22	1.12 ± 0.25	0.65 ± 0.25	0.01 ± 0.02
RT2 Gy × 1 f’x with regorafenib 16 mg/kg × 1 d	0.29 ± 0.17	1.10 ± 0.51	0.19 ± 0.07	0.29 ± 0.19	0.21 ± 0.11	0.02 ± 0.03
RT2 Gy × 1 f’x followed by regorafenib 16 mg/kg × 1 d	0.78 ± 0.27 a	2.28 ± 0.75 d	0.68 ± 0.30 g	1.27 ± 0.64 l	0.59 ± 0.27	0.08 ± 0.06
RT2 Gy × 3 f’x with regorafenib 16 mg/kg × 3 d	0.03 ± 0.03 b	0.55 ± 0.27 e	0.08 ± 0.06 h	0.21 ± 0.09 m	0.13 ± 0.06 r	0.02 ± 0.05
RT2 Gy × 3 f’x followed by regorafenib 16 mg/kg × 3 d	0.29 ± 0.18 c	1.68 ± 0.65 f	0.41 ± 0.24 i	0.99 ± 0.43 n	0.73 ± 0.44 s	0.03 ± 0.05
RT9 Gy × 1 f’x with regorafenib 16 mg/kg × 1 d	0.36 ± 0.33	1.01 ± 0.58	0.14 ± 0.07	0.17 ± 0.14 o	0.18 ± 0.05	0.01 ± 0.02
RT9 Gy × 1 f’x followed by regorafenib 16 mg/kg × 1 d	0.87 ± 0.14	2.39 ± 1.20	0.68 ± 0.45 j	1.01 ± 0.70	0.59 ± 0.34	0.06 ± 0.05
RT9 Gy × 3 f’x with regorafenib 16 mg/kg × 3 d	0.09 ± 0.07	0.70 ± 0.29	0.10 ± 0.08 k	0.25 ± 0.18 p	0.17 ± 0.12 t	0.01 ± 0.02
RT9 Gy × 3 f’x followed by regorafenib 16 mg/kg × 3 d	0.17 ± 0.27	1.16 ± 1.12	0.23 ± 0.31	0.37 ± 0.23 q	0.40 ± 0.43	0.04 ± 0.08

^a RT_{2 Gy × 1 f’x} concurrent with regorafenib × 1 d vs. RT_{2 Gy × 1 f’x} followed by regorafenib × 1 d, p = 0.004. ^b RT_{2 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. regorafenib × 3 d, p = 0.001. ^c RT_{2 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. RT_{2 Gy × 3 f’x} followed by regorafenib × 3 d, p = 0.005. ^d RT_{2 Gy × 1 f’x} followed by regorafenib vs. regorafenib × 1 d, p = 0.036. ^e RT_{2 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. regorafenib × 3 d, p = 0.018. ^f RT_{2 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. RT_{2 Gy × 3 f’x} followed by regorafenib × 3 d, p = 0.003. ^g RT_{2 Gy × 1 f’x} followed by regorafenib vs. regorafenib × 1 d, p = 0.009. ^h RT_{2 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. regorafenib × 3 d, p = 0.01. ⁱ RT_{2 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. RT_{2 Gy × 3 f’x} followed by regorafenib × 3 d, p = 0.008. ^j RT_{9 Gy × 1 f’x} concurrent with regorafenib × 1 d vs. RT_{9 Gy × 1 f’x} followed by regorafenib × 1 d, p = 0.016. ^k RT_{9 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. regorafenib × 3 d, p = 0.016. ^l RT_{2 Gy x 1 f’x} followed by regorafenib vs. regorafenib × 1 d, p = 0.014. ^m RT_{2 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. regorafenib × 3 d, p = 0.001. ⁿ RT_{2 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. RT_{2 Gy × 3 f’x} followed by regorafenib × 3 d, p = 0.001. ^o RT_{9 Gy × 1 f’x} concurrent with regorafenib vs. regorafenib × 1 d, p = 0.009. ^p RT_{9 Gy x 3 f’x} concurrent with regorafenib × 3 d vs. regorafenib × 3 d, p = 0.001. ^q RT_{9 Gy × 3 f’x} followed by regorafenib × 3 d vs. regorafenib × 3 d, p = 0.001. ^r RT_{9 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. regorafenib × 3 d, p = 0.001. ^s RT_{2 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. RT_{2 Gy × 3 f’x} followed by regorafenib × 3 d, p = 0.008. ^t RT_{9 Gy × 3 f’x} concurrent with regorafenib × 3 d vs. regorafenib × 3 d, p = 0.002.